AIDS Vaccine Advocacy Coalition -  Today the sponsors of a randomized clinical trial known as HPTN 052, which is evaluating combination antiretroviral therapy for HIV prevention, announced that randomization would halt due to overwhelming evidence of benefit. Click here to read the full release.

National Institute of Allergy and Infectious Diseases - Men and women infected with HIV reduced the risk of transmitting the virus to their sexual partners by taking oral antiretroviral medicines when their immune systems were relatively healthy, according to findings from a large-scale clinical study sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Click here to read the press release.

Infectious Diseases Society of America - HPTN 052, a study sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH), found that HIV-infected men and women with relatively healthy immune systems who received immediate oral antiretroviral therapy (ART) were 96.3 percent less likely to pass on the infection to their uninfected partners and remained healthier than those whose treatment was delayed. Click here to read the press release.